Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

Also called NCT01375764

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01375764
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Denmark, Finland, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01375764. Randomized; quadruple masking; primary purpose treatment. Start 2011-07-28 (actual); primary completion 2012-05-08 (actual). Results posted on 2015-12-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
Acronym
GAUSS
Condition
Hyperlipidemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Ezetimibe
Intervention (Other)
Placebo to Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01375764
Content hash
4dd7936e4dd4ba090b331775546eaa2f852cae722ed741df6ab49e9acbd545f6